Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nasdaq: NNOX) is at the forefront of revolutionizing medical imaging through its cutting-edge nanotechnology. The company is developing the next generation of X-ray emitters that aim to bring X-ray imaging into the digital era. Its primary offering, the Nanox System, is a combination of hardware and software designed to enhance and modernize medical imaging.
The key component of this system is the Nanox.ARC, a digital X-ray source that incorporates novel nanotechnology to create detailed 3D images. Accompanying this is the Nanox.CLOUD, a cloud-based software platform that enables the delivery of medical screening as a service.
Nano X Imaging Ltd has made significant strides with its Nanox.AI subsidiary, which focuses on deep-learning medical imaging analytics. This arm of the company leverages AI technology to extract valuable clinical insights from routine medical imaging, facilitating early detection and preventative care pathways for patients globally.
One of the latest achievements includes a remarkable study conducted in partnership with the NHS under the Falls and Fragility Fracture Audit Programme (FFFAP). The study revealed a substantial increase in patient identification for spine fractures using the Nanox.AI algorithm, surpassing the national average by up to sixfold. This success highlights the potential of AI-powered solutions in early diagnosis and improved patient care.
Moreover, Nanox has been actively involved in enhancing its AI capabilities with the development of HealthVCF and its updated version HealthOST, both of which received FDA 510(K) clearance. These AI tools focus on highlighting low bone mineral density and measuring the severity of vertebral compression fractures, thus playing a crucial role in osteoporosis management.
The company also offers Second Opinions, an online medical consultation service through its subsidiary USARAD Holdings INC. This platform integrates Nanox.AI's FDA-cleared AI solutions, allowing patients to gain second opinions from medical experts, promoting early detection and preventive management of chronic conditions.
By providing accessible and affordable diagnostic tools, Nanox's vision is to improve early detection and treatment, thereby enhancing global health outcomes and saving lives. The company's comprehensive ecosystem—including Nanox.ARC, Nanox.AI, Nanox.CLOUD, and USARAD's teleradiology services—creates an innovative network connecting medical imaging solutions from scan to diagnosis.
Nanox.AI's Cardiac Solution (HealthCCSng) was featured in multiple scientific presentations at the 2024 SCCT Annual Meeting, showcasing its potential in early detection and preventive care of cardiovascular disease. Key findings include:
1. Brigham & Women's Hospital study: HealthCCSng detected Coronary Artery Calcification (CAC) in over 50% of immune-mediated inflammatory disease patients, associated with increased mortality and cardiovascular risks.
2. Corewell Health implementation: HealthCCSng analyzed 32,650 chest CT scans, identifying 3,721 new patients with medium/high CAC, a 13-fold increase from previous years.
3. Jefferson Einstein Hospital study: HealthCCSng identified 757 patients with high CAC levels, leading to 308 follow-up visits and generating up to $130,000 in revenue.
These studies demonstrate HealthCCSng's clinical and economic benefits in improving cardiovascular risk assessment and patient care.
Nanox Imaging (Nasdaq: NNOX) announced that data from five studies supporting its AI Cardiac Solution, HealthCCSng, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT) from July 18-21 in Washington, D.C.
These studies are by institutions including Brigham & Women’s Hospital, Einstein Jefferson Medical Center, Corewell Health, Massachusetts General Hospital, and Beilinson Medical Center. HealthCCSng uses routine chest CT scans to quantify coronary artery calcium (CAC) levels, a strong predictor of future cardiac events. Patients with high CAC are up to 6x more likely to suffer from cardiac events.
Key presentations include: 'The Frequency, Prevalence, And Outcomes of Incidentally Detected Coronary Artery Calcium Using AI Analysis' by Brittany Weber (July 20, 10:30 AM), and 'Optimizing Preventive Cardiology: Harnessing AI for Early Detection of CAD' by Dr. Chiduzie Madubata (July 19, 9:30 AM - 10:15 AM).
Nano-X Imaging announced the integration of AI solutions into its Second Opinions platform, enhancing its teleradiology services. This advancement leverages deep-learning AI from Nanox.AI to analyze chest and abdominal CT scans, aiming to detect chronic conditions early. The platform, managed by USARAD Holdings, now includes FDA-cleared AI tools: HealthCCSng for coronary artery disease, HealthOST for osteoporosis risk, and HealthFLD for fatty liver disease. These AI findings are vetted by physicians and integrated into patient reports.
Nanox Imaging announced its Q1 2024 financial results, reporting revenues of $2.6 million, up from $2.4 million in Q1 2023. However, the net loss increased to $12.2 million from $11.8 million in the previous year. The company secured agreements with Dandelion Health and Covera Health for its AI solutions and demonstrated its Nanox.ARC scanning technology in New Jersey. Nanox also entered a partnership with Swissray to improve customer support. Despite a decrease in research and administrative expenses, gross loss increased significantly. Cash reserves dropped to $73.3 million from $82.8 million at the end of 2023.
Nanox Imaging, a medical imaging technology company, will announce its financial results for Q1 2024 on May 28, 2024. The report, covering the period ending March 31, 2024, will be released before the market opens. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET to review the results and provide a business update. Interested parties can register for the call or access the live webcast via links available on Nanox's Investor Relations section.
NANO-X IMAGING , the innovative medical imaging technology company, announced that its teleradiology subsidiary, USARAD Holdings, Inc., has been awarded The Joint Commission's Gold Seal of Approval for Ambulatory Health Care Accreditation for the sixth time. This accreditation reflects the organization's commitment to safe and quality patient care.
Nanox, a medical imaging technology company, is set to participate in three investor conferences in May 2024. The conferences include EF Hutton 2024 Annual Global Conference, AGP 2024 Healthcare Conference, and Benchmark 2024 Healthcare House Call Virtual Conference.
FAQ
What is NANO-X IMAGING LTD?
What are the main products of NANO-X IMAGING LTD?
What is the Nanox.AI subsidiary?
What recent achievements has Nanox reported?
What is HealthOST?
What is Second Opinions?
How does Nanox aim to improve global health outcomes?
What is the significance of the Nanox.ARC?
How does Nanox.CLOUD contribute to the Nanox System?
What are some of the benefits of using Nanox.AI's solutions?
